AU2913400A - Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof - Google Patents

Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Info

Publication number
AU2913400A
AU2913400A AU29134/00A AU2913400A AU2913400A AU 2913400 A AU2913400 A AU 2913400A AU 29134/00 A AU29134/00 A AU 29134/00A AU 2913400 A AU2913400 A AU 2913400A AU 2913400 A AU2913400 A AU 2913400A
Authority
AU
Australia
Prior art keywords
mage
mhc
class
immunogenic peptides
peptides presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29134/00A
Other languages
English (en)
Inventor
Paolo Dellabona
Maria Pia Protti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND, Fondazione Centro San Raffaele del Monte Tabor filed Critical SAN RAFFAELE CENTRO FOND
Publication of AU2913400A publication Critical patent/AU2913400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU29134/00A 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof Abandoned AU2913400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI99A0396 1999-02-26
IT1999MI000396A IT1309584B1 (it) 1999-02-26 1999-02-26 Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
PCT/EP2000/001458 WO2000052045A2 (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Publications (1)

Publication Number Publication Date
AU2913400A true AU2913400A (en) 2000-09-21

Family

ID=11382063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29134/00A Abandoned AU2913400A (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Country Status (6)

Country Link
EP (1) EP1161443A2 (ja)
JP (1) JP2002538166A (ja)
AU (1) AU2913400A (ja)
CA (1) CA2364002A1 (ja)
IT (1) IT1309584B1 (ja)
WO (1) WO2000052045A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2008053573A1 (fr) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
JP6313478B2 (ja) * 2014-05-30 2018-04-18 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
CA2278189A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
CN1268738C (zh) * 1997-07-15 2006-08-09 宝生物工程株式会社 细胞毒性t淋巴细胞
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
CA2323632A1 (en) * 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses

Also Published As

Publication number Publication date
WO2000052045A2 (en) 2000-09-08
IT1309584B1 (it) 2002-01-24
EP1161443A2 (en) 2001-12-12
JP2002538166A (ja) 2002-11-12
ITMI990396A1 (it) 2000-08-26
WO2000052045A3 (en) 2001-01-04
CA2364002A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
IL158107A0 (en) Human papillomaviruses vaccine
AU2001244675A1 (en) Aids virus vaccine with the use of sendai virus vector
SI1150712T1 (sl) Pripravek cepiva proti humanem papiloma virusu
AU4139801A (en) Controlled delivery of antigens
IL148247A (en) Vaccine and its uses
AU1812001A (en) Cotton transcription factors and their uses
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU2273701A (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
AU715620C (en) Therapeutic methods and uses
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU6600300A (en) Pneumococcal vaccines
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
GB2370772B (en) Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU2002210407A1 (en) Therapeutic vaccine formulations containing chitosan
AU5977700A (en) Vaccines
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU1911301A (en) Novel bacterial isolate and the preparation and use of its active metabolites
HUP0202770A3 (en) Human papilloma virus vaccine
EP1194548A4 (en) NOVEL PYRRHOCORICIN-DERIVED PEPTIDES AND METHODS OF IMPLEMENTING THE SAME
AU6158700A (en) Vaccine
AUPQ257199A0 (en) Vaccine antigens of moraxella
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase